Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
NCT01316185
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class
Stopped
the enrollment was slow and never completed.
Conditions
Hepatitis D
Interventions
DRUG:
EBP921
Sponsor
Eiger BioPharmaceuticals